報價延遲最少15分鐘:2025/11/04 02:36 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.91/-0.81
|
|
企業價值
37.60M
|
| 資產負債 |
|
每股賬面淨值
0.13
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/04 02:36 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01:proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment;and LTI-05 and others. |
